Visit WTR Logo
Subscribe now

Valuation

The IP story to engage the c-suite is there, but it takes bravery to tell it

Saturday Opinion: After a highly successful IPBC in Seattle earlier this week, it is clear that there has never been a better time to take the value creation gospel to the boardroom

The IP story to engage the c-suite is there, but it takes bravery to tell it
How Aon helps lenders and borrowers manage risk in IP-backed deals
18 Nov 2021

How Aon helps lenders and borrowers manage risk in IP-backed deals

Brian Hinman, chief commercial officer at Aon IP Solutions, tells IAM how the group facilitates IP-backed funding deals centred on high-quality assets

A $650 million deal is the latest in a growing number of CRISPR IP transactions
5 Nov 2021

A $650 million deal is the latest in a growing number of CRISPR IP transactions

Last week’s licensing agreement between Mammoth and Vertex shows how deal-making in the space is gathering momentum

Latest

View all
2 Nov 2021

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine Read more

1 Nov 2021

Flexibility crucial to growing appeal of big money drug royalty transactions, says leading deal-maker

In the wake of the firm’s latest $250 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband gives the inside track on life sciences IP-backed revenue sales Read more

29 Oct 2021

Nokia Technologies boosts revenues and profits in strong Q3 patent licensing performance

Royalties grow on the back of new deals and renewals; company also shares new details on legal fight with Oppo, which does not appear to have significantly dimmed income outlook Read more

22 Oct 2021

Hub and spoke IP strategies are generating billions of dollars in biopharma

New Crinetics spin-off is more evidence of the growing influence of models designed to monetise non-core life sciences assets Read more

News

View all
22 Dec 2020

The keys to effective IP monetisation

Patent licensing is as much an art as it is a science, explain some of those featured in the new IAM Strategy 300 Global Leaders guide Read more

19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

9 Nov 2020

Pfizer’s covid vaccine found 90% effective, but raises IP questions

Company CEO proclaims “a great day for science and humanity”, but there are patent, know-how and data uncertainties to overcome Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

Analysis

View all
19 Oct 2021

Investment in medical device IP is surging

Diagnostic innovation buyouts drive resurgence of med-tech deal-making Read more

19 Oct 2021

Ericsson turns in strong licensing quarter with Apple renewal looming

Continued impact of Samsung deal pushes Swedish company’s royalty take near $300 million – but executives warn upcoming re-negotiations could produce temporary disruption again Read more

7 Oct 2021

Four IP takeaways from Merck’s $11.5 billion Acceleron acquisition

Merck has struck the biggest life sciences M&A deal of 2021 so far. Here are the four key IP-related takeaways. Read more

5 Oct 2021

Amgen’s Otezla win vindicates multi-billion-dollar IP purchase

US federal court victory sets up the $13.4 billion drug for exclusivity until 2028 Read more

Insights

View all
8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more

1 Oct 2017

A round-up of IP-related quotes, observations and opinions from the recent past …

A round-up of IP-related quotes, observations and opinions from the recent past …

Read more

30 Sep 2016

McRO gives hope to US patent owners, but Section 101 uncertainty remains

After two years of uncertainty and no little gloom, a recent Federal Circuit decision may just herald the long-awaited swing-back in the pendulum that software patent owners in the United States have been waiting for. Some, though, still believe that Congress must bite the bullet and take a look at Section 101 Read more

1 Aug 2016

Brexit leaves the UPC in limbo – and that’s no bad thing

The UK vote to leave the European Union may have surprised and disappointed many in the IP community, but a rush to bypass the decision and implement the unitary patent package would be a mistake

Read more

Trending

1

The IP story to engage the c-suite is there, but it takes bravery to tell it

2

How to value a professional services firm in an M&A transaction

3

How Aon helps lenders and borrowers manage risk in IP-backed deals

4

Your guide to covid-19 vaccine stakeholders’ IP strategies

5

IBM has sold over 15,000 patents since 1991; Google is its biggest customer